Avalo Therapeutics Inc. (AVTX)
Avalo Therapeutics Statistics
Share Statistics
Avalo Therapeutics has 10.67M shares outstanding. The number of shares has increased by 931.97% in one year.
| Shares Outstanding | 10.67M |
| Shares Change (YoY) | 931.97% |
| Shares Change (QoQ) | 1.99% |
| Owned by Institutions (%) | 61.5% |
| Shares Floating | 8.49M |
| Failed to Deliver (FTD) Shares | 592 |
| FTD / Avg. Volume | 0.72% |
Short Selling Information
The latest short interest is 115.73K, so 1.08% of the outstanding shares have been sold short.
| Short Interest | 115.73K |
| Short % of Shares Out | 1.08% |
| Short % of Float | 1.08% |
| Short Ratio (days to cover) | 1.98 |
Valuation Ratios
The PE ratio is -1.72 and the forward PE ratio is -1.25. Avalo Therapeutics's PEG ratio is 0.02.
| PE Ratio | -1.72 |
| Forward PE | -1.25 |
| PS Ratio | 136.95 |
| Forward PS | 3.5 |
| PB Ratio | 0.45 |
| P/FCF Ratio | -1.23 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Avalo Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.96, with a Debt / Equity ratio of 0.
| Current Ratio | 19.96 |
| Quick Ratio | 19.96 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | -20.65 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $19.17K |
| Profits Per Employee | $-1.53M |
| Employee Count | 23 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 114K |
| Effective Tax Rate | -0.33% |
Stock Price Statistics
The stock price has increased by -67.56% in the last 52 weeks. The beta is 0.72, so Avalo Therapeutics's price volatility has been higher than the market average.
| Beta | 0.72 |
| 52-Week Price Change | -67.56% |
| 50-Day Moving Average | 6.84 |
| 200-Day Moving Average | 9.14 |
| Relative Strength Index (RSI) | 36.94 |
| Average Volume (20 Days) | 82.36K |
Income Statement
In the last 12 months, Avalo Therapeutics had revenue of 441K and earned -35.13M in profits. Earnings per share was -4.32.
| Revenue | 441K |
| Gross Profit | -26.83M |
| Operating Income | -68.51M |
| Net Income | -35.13M |
| EBITDA | -68.51M |
| EBIT | -31.7M |
| Earnings Per Share (EPS) | -4.32 |
Balance Sheet
The company has 134.55M in cash and 568K in debt, giving a net cash position of 133.98M.
| Cash & Cash Equivalents | 134.55M |
| Total Debt | 568K |
| Net Cash | 133.98M |
| Retained Earnings | -370.26M |
| Total Assets | 150.73M |
| Working Capital | 131.93M |
Cash Flow
In the last 12 months, operating cash flow was -49.06M and capital expenditures 0, giving a free cash flow of -49.06M.
| Operating Cash Flow | -49.06M |
| Capital Expenditures | 0 |
| Free Cash Flow | -49.06M |
| FCF Per Share | -6.04 |
Margins
Gross margin is -6084.81%, with operating and profit margins of -15535.6% and -7965.76%.
| Gross Margin | -6084.81% |
| Operating Margin | -15535.6% |
| Pretax Margin | -7939.91% |
| Profit Margin | -7965.76% |
| EBITDA Margin | -15535.6% |
| EBIT Margin | -15535.6% |
| FCF Margin | -11123.81% |
Dividends & Yields
AVTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AVTX is $36, which is 640.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $36 |
| Price Target Difference | 640.7% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Dec 29, 2023. It was a backward split with a ratio of 1:240.
| Last Split Date | Dec 29, 2023 |
| Split Type | backward |
| Split Ratio | 1:240 |
Scores
| Altman Z-Score | -1.52 |
| Piotroski F-Score | 1 |